Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma (JCOG0601)

Trial Profile

Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma (JCOG0601)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Dec 2014

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2014 Status changed from recruiting to active, no longer recruiting according to University Hospital Medical Information Network - Japan.
    • 20 Jan 2014 Planned number of patients changed from 360 to 422 as reported by University Hospital Medical Information Network - Japan.
    • 08 Oct 2013 Planned End Date changed from 1 Dec 2015 to 4 Dec 2017 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top